The fifth round of national procurement, implementation time announced

The fifth batch of national procurement, 5 locations have clear execution time

01 Five places to clarify the execution time

Recently, many provinces and cities issued the latest announcements on the implementation of the fifth batch of national centralized procurement.

Henan

On August 31, the Henan Provincial Medical Security Bureau issued the "Notice on Doing a Good Job in the Implementation of the Fifth Batch of National Organized Drug Centralized Procurement and Chongqing Pharmaceutical Procurement Alliance to ensure supply, stable price and quantity procurement

Among them, the fifth batch of nationally organized drugs for centralized procurement of selected varieties of gemcitabine hydrochloride for injection, lansoprazole for injection, palonosetron hydrochloride injection (1.

The document also explained the timing of the work before the implementation of the fifth batch of centralized procurement

1.

Before September 1, the medical insurance departments at all levels will release the agreed purchase quantities of the selected drugs level by level, and decompose them to their medical institutions

2.

Prior to September 13, the selected companies shall, in accordance with relevant requirements, do a good job in maintaining the qualifications of the selected companies and maintaining the information of the selected products

3.

Before September 18, pharmaceutical institutions, selected enterprises, and operating companies log on to the provincial pharmaceutical procurement platform to confirm the tripartite purchase and sale contract.

4.

Before September 26, the Provincial Public Resources Trading Center organized the fifth batch of national organizations to centrally purchase the price adjustment of non-selected drugs with the same generic name

5.

Starting from September 22, the Provincial Public Resource Trading Center will uniformly adjust the prices of related drugs

Tibet

On August 31, the Drug Procurement Service Management Center of Tibet Autonomous Region issued the "Notice on Carrying out the Fifth Batch of Centralized Procurement of National Organizations and Centralized Procurement of the "Eight Provinces and Two Districts" Inter-provincial Alliance", clearly stating that it will be 10 The fifth batch of national selection results will be officially launched on the 1st

In addition, the notice requires companies to maintain information from September 1 to September 5, that is, to declare the work of linking to the Internet

The notice also added that in accordance with the relevant provisions of the "Six Provinces and Two Districts" Inter-provincial Alliance Drug Centralized Purchase Documents, the "six provinces and two areas" Inter-Provincial Alliance Drug Centralized Purchase of Drugs Selected Product Lipoic Acid Injection (Small Volume Injection) Liquid) and lansoprazole for injection (sterile powder for injection) will first implement the results of the "six provinces and two districts".
After the results of the "six provinces and two districts" in this procurement cycle are completed, the second year will be implemented.
The results of the five batches of national centralized procurement
.

Shanghai

On August 30, Shanghai Sunshine Pharmaceutical Purchasing Network released the "Work Tips (1) on the Implementation of the Results of the Fifth Batch of National Organized Drug Centralized Procurement"
.
According to the notification, the results of the fifth batch of national-organized centralized drug procurement are expected to be formally implemented in Shanghai in late October
.

The document requires medical institutions to make preparations for procurement and execution in advance
.
For example, convene a pharmaceutical committee to simplify and speed up the procurement process and smooth the general pharmaceutical channels
.
At the same time, the document pointed out that medical institutions should purchase the selected drugs through the drug dealers or distribution companies designated by the selected companies, and the payment time should not exceed 30 days
.

In addition, the document requires agencies to ensure priority in the procurement and use of selected drugs, strengthen publicity and training, and strengthen risk assessment and plan formulation for the use of selected drugs that may lead to adjustments in patients' medications to ensure a smooth transition
.

In addition to the above three regions, Liaoning and Xinjiang have determined the implementation time of the fifth batch of centralized procurement
.

Liaoning

The Centralized Procurement Network of Medicines and Medical Consumables in Liaoning Province issued the "Notice Concerning the Implementation of the Fifth Batch of National Organizations of Centralized Procurement of Drugs (Liaoning) to Supplement the Network for Selected Drugs"
.
The document pointed out that Liaoning Province plans to start the implementation of the fifth batch of national organizations' centralized procurement (Liaoning) selection results at the end of October
.

Xinjiang

The Xinjiang Uygur Autonomous Region Medical Insurance Bureau issued the "Notice on Doing a Good Job in the Implementation of the Results of the Fifth Batch of National Organizations and the Chongqing Ten-province Alliance Organization of Drug Centralized Procurement
.
" The notice clearly stated that the fifth batch of national procurement in Xinjiang will be implemented on September 15, 2021
.

On the occasion of the announcement of the results of the fifth batch of national selection, "CCTV News" reported that it is expected that patients will be able to receive reduced-price drugs in October this year.
Judging from the announcement time of the above-mentioned regions where the implementation time is basically clear, this estimate is not much different.
, I believe that more and more regions will release specific implementation time in the near future
.

02Recent progress of landing

Up to now, many regions have also released the latest progress of the fifth batch of centralized procurement
.

On August 31, the Ningxia Pharmaceutical Procurement Platform issued the "Notice on Announcement of the Qualification Examination Results of the Fifth Batch of National Organized Drug Centralized Procurement (Ningxia)"
.
The notice shows that from August 24 to August 31, the Ningxia Public Resources Trading Service Center reviewed the fifth batch of nationally selected Ningxia pharmaceutical qualification documents.
At present, the qualification review has been completed, with 61 drug varieties and 91 drugs The product specification passed the audit
.

On August 31, Quanyao.
com issued the "Notice on Announcement of the Fifth Batch of Nation-Organized Drug Centralized Procurement of Non-selected Drug Manufacturers and Product Registration Information Review Results".
The notice showed that the Shenzhen trading platform has completed the fifth batch of nationally organized drug concentration.
Procurement of non-selected drug manufacturers and product registration information review, review of the revised information submitted by companies that failed the review, and analysis and processing of received applications (submissions)
.

On August 30, the Guangzhou Public Resources Trading Center issued the "Notice on Carrying out the Fifth Batch of National Organizations for Centralized Procurement of Drugs and Confirming the Price of Selected Drugs (Supplementary Packaging)", announcing that the Guangzhou Pharmaceutical Group Procurement Platform is now launching the fifth batch of national organizations.
To confirm the price of selected drugs (supplementary packaging) for centralized procurement and use of drugs, relevant units are required to log on to the Guangzhou Pharmaceutical Group’s procurement platform for confirmation before 17:00 on September 2 Net, the specific time will be notified separately
.

On August 30, the Jiangxi Provincial Pharmaceutical Procurement Service Platform issued the "Notice on Publicizing the Price Declaration Information of the Fifth Batch of National Organizations Procurement of Non-selected Drugs".
The period is from August 30th to September 3rd at 5:00 pm.
Enterprises that have objections to the published content or need to supplement and update the price are required to submit relevant materials and adjustments in a timely manner
.

According to Cyberlane’s incomplete analysis, up to now, the latest situation of the fifth batch of centralized procurement in various regions is as follows:

Graphics: Cyber ​​Blue

03 Centralized procurement rules gradually mature

The fifth round of national procurement involves 61 varieties
.
The most obvious difference from the previous batches of centralized procurement is that this time there are 30 injections, while the first four injections only have 3, 1, 3, and 8, which means that the fifth batch of injections has almost It is twice the sum of the first four batches
.

Behind this change reflects the development trend of centralized sourcing becoming more and more mature
.

In the early stage of mass collection, due to the large quality variability and high drug risk, fewer injections were included.
However, with the progress of the consistency evaluation of the quality and efficacy of injections, more and more injections were over-evaluated.
, Laid the foundation for the adoption of a large number of injections in the fifth batch
.

In fact, in the first five batches of centralized procurement, different dosage forms have been explored, and slow-release and controlled-release dosage forms, chewable tablets, orally disintegrating tablets, oral solutions, eye drops, granules, and inhalants have been gradually included
.
In addition to the different formulations of chemical drugs, the volume purchase is being considered to expand to a wider range
.

The General Office of the State Council clearly stated in the "Opinions on Promoting the Normalized and Institutionalized Development of Drug Centralized and Volume Procurement", focusing on including drugs with large amounts and high purchase amounts in the basic medical insurance drug catalog, and gradually covering all types of drugs
.
Judging from recent documents, proprietary Chinese medicines and insulin have officially entered the focus of centralized procurement
.
However, the current procurement plan for related drugs is still under discussion
.

A few days ago, the Hubei Medical Insurance Bureau issued the "Letter on Inviting Participation in the Centralized Procurement of Proprietary Chinese Patent Medicines in Provincial Cross-Regional Alliances" and began to give specific methods for grouping proprietary Chinese medicines, that is, to classify them based on the product group of the same prescription and the route of administration
.

Based on the way the products of the same formula are grouped, some experts pointed out that even if the drugs are the same, if the dosage is different, and the processing method is different, there will still be certain differences
.
Therefore, there is still some controversy whether it is completely reasonable to put drugs together in competition in this way
.

Regarding insulin, on the evening of August 18, the National Medical Insurance Administration's solicitation of the "National Organization of Insulin Concentrated Procurement Plan (Draft for Solicitation of Comments)" flowed out of the industry
.
The document stipulates that the second-generation and third-generation insulins are adopted in this insulin country.
Each generation is divided into three groups: quick-acting, basic and pre-mixed according to the duration of insulin effectiveness.
The generic names are unit competition, group competition, and group quotation
.

According to the above-mentioned group bidding principle, there are many production companies in each group of the second generation, and basically each group has 7-8 companies, but the competition of the third-generation insulin is relatively loose, mostly around 2-3
.
Under this circumstance, whether the company has enough incentive to cut prices is still questionable
.

In addition to the price, the quality of the product and the stability of the supply need to be considered in the purchase of quantity
.
In particular, insulin biologics products are relatively complicated to use and have a long-term nature, and the stability of clinical medication is very important
.
In addition, the production of biological products is difficult and production capacity is limited.
Maintaining a stable supply after winning the bid is also a test for the production capacity of the company
.

Taking into account relevant factors, the country has set up a reporting method of "generic name + brand" that is different from the generic name of chemical generic drugs, which highlights the autonomy of medical institutions, guarantees the stability of clinical drug use, and at the same time guarantees the stable supply of enterprises.
Set a 50% maximum capacity limiting factor
.

Judging from the exploration of the centralized procurement plan for Chinese patent medicines and insulin products, mass procurement is still undergoing continuous development and improvement.
I believe that more products will be included in the future, so as to achieve the full harvest
.